PT - JOURNAL ARTICLE AU - Landlinger, Christine AU - Tisakova, Lenka AU - Oberbauer, Vera AU - Schwebs, Timo AU - Latka, Agnieszka AU - Van Simaey, Leen AU - Vaneechoutte, Mario AU - Guschin, Alexander AU - Swidsinski, Sonja AU - Swidsinski, Alexander AU - Corsini, Lorenzo TI - Engineered phage endolysin eliminates <em>Gardnerella</em> in bacterial vaginosis without damaging the healthy vaginal microbiome AID - 10.1101/2020.10.21.20216853 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.21.20216853 4099 - http://medrxiv.org/content/early/2020/10/27/2020.10.21.20216853.short 4100 - http://medrxiv.org/content/early/2020/10/27/2020.10.21.20216853.full AB - Background Bacterial vaginosis is characterized by an imbalance of the vaginal microbiome in which the normally predominant lactobacilli are replaced by other bacterial species. Initiated by strains of the bacterium Gardnerella, a characteristic biofilm forms on the vaginal epithelium, explaining the typical presence of clue cells. This biofilm contributes to the resilience of the bacteria to antibiotic treatment, which may explain the frequent recurrence of BV.Objective In this study, we investigate whether a therapy based on bacteriophage endolysins which specifically lyse Gardnerella, in particular the drug candidate PM-477, might be a promising alternative to broad-spectrum antibiotics and antiseptics.Study design To identify Gardnerella specific endolysins, we searched for endolysin-encoding sequences in regions of Gardnerella genomes that are of prophage origin. This search identified fourteen homologous genes predicted to encode 1,4-beta-N-acetylmuramidase-type endolysins. When expressed in Escherichia coli and purified, the recombinant proteins demonstrated strong bactericidal activity against four different Gardnerella species. By shuffling the N-terminal catalytic domains and C-terminal cell wall-binding domains between the homologues, we produced 81 chimeric endolysins. These endolysins were tested for their activity and specificity in vitro and ex-vivo on vaginal samples from fifteen BV positive patients. Fluorescence in situ hybridization was used for visualization.Results Several engineered endolysins were 10-fold more active than the most active wild-type enzymes. When tested against a panel of 20 Gardnerella strains, the most active endolysin, called PM-477, showed minimum inhibitory concentrations of 0.13–8 µg/ml. PM-477 had no effect on Lactobacillus strains or other species of vaginal bacteria. Furthermore, the efficacy of PM-477 was tested on vaginal samples from fifteen patients with either first time or recurring bacterial vaginosis. In fourteen cases, PM-477 killed the Gardnerella bacteria and physically dissolved the biofilms without affecting the remaining vaginal microbiome.Conclusion The high selectivity and effectiveness in eliminating Gardnerella, both in cultures of isolated strains as well as in clinically derived samples of natural polymicrobial biofilms, makes PM-477 a promising drug candidate and an alternative to antibiotics for the treatment of bacterial vaginosis, especially in patients with frequent recurrence.Competing Interest StatementConflicts of interests have been declared by the following authors: CL, LT, VO, are employees of PhagoMed Biopharma GmbH at the time of the study. LC holds shares in PhagoMed Biopharma GmbH and is the inventor on a patent application related to the work described here. The research of AS, AL, LVS and MV has been supported financially by PhagoMed Biopharma GmbH.Funding StatementThis study was supported by the Austrian Research Promotion Agency (FFG).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Charite ethical committee EA1 /088110.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data is disclosed in the manuscript.